March 19, 2008
Targeted Molecular Diagnostics Launches PhosphoGuard(TM) — a Preservative for Phosphorylated Proteins
Targeted Molecular Diagnostics, LLC (TMD) announces the availability of the PhosphoGuard(TM) kit for preservation of phosphoproteins during tissue fixation and processing.
When used as an additive to conventional fixatives, PhosphoGuard(TM) can prevent degradation of phosphorylated or "activated" proteins in patient tissue or xenograft specimens. Phosphorylated proteins are useful markers that may be essential in predicting patient response or resistance to targeted cancer therapies. Endogenous phosphatases are ubiquitously present and often impede the detection of these phosphorylated antigens by immunohistochemistry (IHC). TMD has formulated a proprietary solution of broad-spectrum phosphatase inhibitors in the PhosphoGuard(TM) kit which has been used in several Phase II and III oncology clinical trials for targeted therapies such as Tykerb.
PhosphoGuard(TM) is available in a 10-test research use format or as a comprehensive single use kit designed for use in clinical trials. For more information about PhosphoGuard(TM), please contact TMD at [email protected] or toll free 866-897-7350.
Targeted Molecular Diagnostics, LLC (www.tmdlab.com) is focused on the development and performance of targeted cancer diagnostic tests to enable personalized cancer treatment. TMD has pioneered the use of biomarkers to advance clinical trials for biopharmaceutical companies and is involved in numerous ongoing studies and clinical programs. The company was founded in 2004, is privately held, and has clinical and research laboratories located in the Chicago suburb of Westmont, IL. For more information call 866-897-7350 or visit www.tmdlab.com.
Targeted Molecular Diagnostics 610 Oakmont Lane Westmont, Il 60559 Contact: Andrea Jones 630-789-1233 www.tmdlab.com
SOURCE: Targeted Molecular Diagnostics (TMD)